Shijiazhuang Pharma Group (石药创新) subsidiary, Giant Biologics (巨石生物), has entered into a strategic collaboration with AstraZeneca to develop novel small interfering RNA (siRNA) drug candidates. AstraZeneca will pay an upfront fee of $30 million, with potential milestone payments totaling up to $5.4 billion for development and $1.2 billion for sales if all conditions are met. Additionally, Giant Biologics' injectable drug SYS6043 has been designated a breakthrough therapy by China's National Medical Products Administration for treating platinum-resistant ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. AI
RANK_REASON Partnership between a subsidiary of a Chinese pharmaceutical company and a major multinational pharmaceutical company, involving significant potential financial milestones and a breakthrough therapy designation. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
